4523
4,653.00
-15.00 (-0.32%)
JPY · TSE
52-week range
3,660.00
5,233.00
Trading at 63% of the 52-week range
Market Cap
1.32T
P/E Ratio
34.14
Forward P/E
32.68
Book Value
3,216.02
Div. Yield
3.46%
% Institutions
56.74%
% Insiders
2.18%

1 Year

-6.4%

3 Year

-43.4%

10 Year

-6.0%
Description

Eisai Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals in Japan. The company operates through pharmaceuticals business and other business segments. It offers Lenvima, a multi-kinase inhibitor which is involved in tumor angiogenesis or tumor malignancy; LEQEMBI, a humanized IgG1 monoclonal antibody against amyloid-beta (Aß) protofibrils; and Dayvigo, a novel small molecule compound. The company also provides prescription drugs; and over-the-counter drugs, as well as focuses on neurology and oncology, and other therapeutic areas. It operates in Europe, the Middle East, Africa, Russia, Oceania, the Americas, China, East Asia, the Global South, and internationally. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.

Company Information

Company Name
Eisai Co. Ltd.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Exchange
TSE
ISIN: JP3160400002
Currency: JPY
Full Time Employees: 10,543
Phone: 81 3 3817 3700
Website: eisai.co.jp
Fiscal Year End: March
IPO Date: Sep 01, 1961
Description:

Eisai Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals in Japan. The company operates through pharmaceuticals business and other business segments. It offers Lenvima, a multi-kinase inhibitor which is involved in tumor angiogenesis or tumor malignancy; LEQEMBI, a humanized IgG1 monoclonal antibody against amyloid-beta (Aß) protofibrils; and Dayvigo, a novel small molecule compound. The company also provides prescription drugs; and over-the-counter drugs, as well as focuses on neurology and oncology, and other therapeutic areas. It operates in Europe, the Middle East, Africa, Russia, Oceania, the Americas, China, East Asia, the Global South, and internationally. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.

Address:

4-6-10 Koishikawa, Tokyo, Japan, 112-8088

People

Directors & Officers

Name Title Year Born
Mr. Haruo Naito CEO, Representative Corporate Officer & Director 1947
Mr. Keisuke Naito Representative Corporate Officer, EVP, COO & Chief Growth Officer 1988
Mr. Terushige Iike Executive VP, Rep. Corporate Officer & Chief Business Officer 1963
Dr. Lynn D. Kramer FAAN, M.D. VP & Chief Clinical Officer 1950
Ms. Yanhui Feng Senior Vice President 1972
Mr. Takuya Oyama Vice President, Chief Financial Officer & Chief IR Officer 1977
Ms. Akiko Nakahama Vice President of Japan Regulatory Affairs, Manufacturing, Quality & Technology 1968
Makoto Hoketsu VP & Chief Information Officer 1968
Dr. Katsutoshi Ido VP, Chief Scientific Officer & Head of DHBL Discoverry 1978
Mr. Teruyuki Masaka VP and Chief HR Officer, Corporate Communications, Sustainability & General Affairs 1978

Financial Highlights

Market Cap: $1,317.48B
EBITDA: $96.13B
P/E Ratio: $34.14
PEG Ratio: $26.43
Book Value: $3.22K
Dividend/Share: $160.00
Dividend Yield: 3.46%
Earnings/Share: $136.75
Profit Margin: 4.94%
Operating Margin: 10.55%
ROA (TTM): 2.40%
ROE (TTM): 4.96%
Revenue (TTM): $857.06B
Revenue/Share (TTM): $3.04K
Earnings Growth (YOY): 26.00%
Revenue Growth (YOY): 15.60%

Valuation Metrics

Enterprise Value: $1,243.70B
Trailing P/E: 34.14
Forward P/E: 32.68

Shares Statistics

Shares Outstanding: 282.24M
Shares Float: 281.16M
% Insiders: 2.18%
% Institutions: 56.74%

Stock Price History

1 Year Price History

3 Years Price History

10 Years Price History

Financial Charts

Revenue, Net Income & Operating Cash Flow (Yearly)

Revenue, Net Income & Operating Cash Flow (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$825.38B
Cost of Goods Sold
adjust
$-191.22B
Gross Profit
subtotal
$634.16B
SG&A
adjust
$-435.29B
R&D
adjust
$-158.66B
Operating Income
subtotal
$40.21B
Other / Non-Operating Items
adjust
$-1.65B
Net Income
subtotal
$38.56B

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about 4523.TSE!